User:Immcarle54/sandbox
 | This is a user sandbox of Immcarle54. You can use it for testing or practicing edits. This is not the sandbox where you should draft your assigned article for a dashboard.wikiedu.org course. To find the right sandbox for your assignment, visit your Dashboard course page and follow the Sandbox Draft link for your assigned article in the My Articles section. |
Article Evaluation
Anti-Histone Antibodies
The information on this page is all relevant to the topic but is very sparse. It contains only neutral facts, which are supported by neutral outside sources; however, one of the links is broken.
Because this article is so brief (2 sentences), I am certain that there is important information about these antibodies that can be learned from primary literature. There have been no major updates since the page was created 8 years ago.
There have been no conversations on the Talk page, aside from marking the page as in scope of the WikiProject Medicine and a Stub article of Low importance.
We have not yet begun discussing adaptive immunity in class, but I believe after we talk about antibodies next week, I will have the tools to begin reading about autoimmunity and digging into primary literature on this topic specifically.
Sections to Include
Lead paragraph
Anti-histone antibodies are autoantibodies that are a subset of the anti-nuclear antibody family, that target histones or histone complexes.[1] They were first reported by Henry Kunkel, H.R. Holman, and H.R.G. Dreicher in their studies of cellular causes of Lupus erythematosus in 1959-60.[2] [3] Today, anti-histone antibodies are still used as a marker for Systemic Lupus Erythematosus, but are also implicated in other autoimmune diseases like Sjogren's Syndrome, dermatomyositis, or rheumatoid arthritis.[4][5]
Specificity
Anti-Histone Antibodies target 5 major classes of histones: H1, H2A, H2B, H3, and H4.[6] There is evidence that IgG and IgM anti-histone antibodies produced as a result of different drug exposures are specific to epitopes of different histone complexes.[7] Highly modified histones have been shown to prompt a greater immune response. [8]
Detection
Anti-Histone antibodies can be clinically detected using an ELISA assay. A blood sample is required for the test.[9][10]
Indirect Immunofluorescence can also be used to detect anti-histone antibodies. Homogeneous, diffuse staining indicates the presence of anti-histone antibodies, chromatin, and some double-stranded DNA.[11]
Implications in Disease
Patients with lupus induced by procainamide will have a positive test for anti-histone antibodies 96% of the time, and patients whose lupus was induced by penicillamine, isoniazid, or methyldopa will have a positive test 100% of the time. In patients with Rheumatoid arthritis, Felty's syndrome, Sjogren's Syndrome, systemic sclerosis, and primary biliary cirrhosis, anti-histone antibodies are present 70% of the time. Anti-histone antibodies may also be present in Alzheimers and dementia patients.[12]
A value of greater than 1.5 units relative to a control serum is considered a positive ELISA test for the anti-histone antibodies. Patients with Drug-Induced Lupus Erythematosus typically have positive tests for anti-histone antibodies but do not have indications for double-stranded DNA autoantibodies. Patients with idiopathic Systemic Lupus Erythematosus have both types of autoantibodies. Thus, this test can be useful in distinguishing these two illnesses. [13]
Sources
Mayo Clinic Clinical Recommendations [14]
Determining diagnostic markers for neuropsychiatric systemic lupus erythematosus [15]
Accuracy of histone antibodies in systemic lupus erythematosus [16]
Mouse study with histone antibodies [17]
Looking at increased levels of autoantibodies in disease model [18]
Initial paper reporting antihistone antibodies [19]
- ^ Muller, Sylviane (2014). Chapter 23 - Histone Autoantibodies, In Autoantibodies (Third ed.). San Diego, CA. p. 195. ISBN 9780444563781. Retrieved 13 January 2018.
{{cite book}}: CS1 maint: location missing publisher (link) - ^ Holman, Henry R.; Deicher, H.R.G.; Kunkel, H.G. (July 1959). "The L.E. Cell and L.E. Serum Factors". Bulletin of the New York Academy of Medicine. 35 (7): 409–418. PMID PMC1806184. Retrieved 11 February 2018.
{{cite journal}}: Check|pmid=value (help) - ^ Holman, H.R.; Deicher, H.R.G.; Kunkel, H.G. (January 1, 1960). [doi: 10.1002/9780470719169.ch20 Chapter 20. Multiple "Autoantibodies" to Cell Constituents in Systematic Lupus Erythematosus. In: Ciba Foundation Symposium - Cellular Aspects of Immunity]. Chichester, UK: John Wiley & Sons. pp. 429–449. Retrieved 30 January 2018.
{{cite book}}: Check|url=value (help) - ^ Kumar, Vinay; Abbas, Abul; Aster, Jon (2018). Robbins Basic Pathology (10 ed.). Philadelphia, PA: Elsevier. pp. 150–157. ISBN 978-0-323-35317-5.
{{cite book}}:|access-date=requires|url=(help) - ^ Inova Diagnostics. "Quanta Lite Histone". Inova Diagnostics a Werfen Company. Retrieved 8 February 2018.
- ^ Cozzani, Emanuele; Drosera, Massimo; Gasparini, Giulla; Parodi, Aurora (Feb. 6, 2014). "Serology of Lupus Erythematosus: Correlation between Immunopathological Features and Clinical Aspects". Autoimmune Diseases. doi:10.1155/2014/321359. PMID PMC3932647.
{{cite journal}}:|access-date=requires|url=(help); Check|pmid=value (help); Check date values in:|date=(help)CS1 maint: unflagged free DOI (link) - ^ Burlingame, Rufus; Rubin, Robert (August 1991). Journal of Clinical Investigation. 88: 680–690. doi:10.1172/JCI115353.
{{cite journal}}:|access-date=requires|url=(help); Missing or empty|title=(help) - ^ Dema, Barbara; Charles, Nicolas (4 Jan, 2016). "Autoantibodies in SLE: Specificities, Isotypes, and Receptors". Antibodies. 1 (5). doi:10.3390/antib5010002.
{{cite journal}}:|access-date=requires|url=(help); Check date values in:|date=(help)CS1 maint: unflagged free DOI (link) - ^ Mayo Clinic, Histone Autoantibodies, https://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/80944
- ^ Inova Diagnostics. "Quanta Lite Histone". Inova Diagnostics a Werfen Company. Retrieved 8 February 2018.
- ^ Kumar, Vinay; Abbas, Abul; Aster, Jon (2018). Robbins Basic Pathology (10 ed.). Philadelphia, PA: Elsevier. pp. 150–157. ISBN 978-0-323-35317-5.
{{cite book}}:|access-date=requires|url=(help) - ^ Cozzani, Emanuele; Drosera, Massimo; Gasparini, Giulla; Parodi, Aurora (Feb. 6, 2014). "Serology of Lupus Erythematosus: Correlation between Immunopathological Features and Clinical Aspects". Autoimmune Diseases. doi:10.1155/2014/321359. PMID PMC3932647.
{{cite journal}}:|access-date=requires|url=(help); Check|pmid=value (help); Check date values in:|date=(help)CS1 maint: unflagged free DOI (link) - ^ Mayo Clinic, Histone Autoantibodies, https://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/80944
- ^ Mayo Clinic, Histone Autoantibodies, https://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/80944
- ^ Protein array autoantibody profiles to determine diagnostic markers for neuropsychiatric systemic lupus erythematosus. Rheumatology (Oxford). 2017 Aug 1;56(8):1407-1416. doi: 10.1093/rheumatology/kex073.
- ^ High diagnostic accuracy of histone H4-IgG autoantibodies in systemic lupus erythematosus. Rheumatology (Oxford). 2017 Dec 15. doi: 10.1093/rheumatology/kex462.
- ^ B Cell Tolerance to Deiminated Histones in BALB/c, C57BL/6, and Autoimmune-Prone Mouse Strains. Front Immunol. 2017 Mar 30;8:362. doi: 10.3389/fimmu.2017.00362. eCollection 2017.
- ^ Leiss H, Salzberger W, Jacobs B, Gessl I, Kozakowski N, Blüml S, et al. (2017) MicroRNA 155-deficiency leads to decreased autoantibody levels and reduced severity of nephritis and pneumonitis in pristane-induced lupus. PLoS ONE 12(7): e0181015. https://doi.org/10.1371/journal.pone.0181015.
- ^ Kunke, H. G., Holmanan, H. R. and Deicher, H. R. G. (1960) Multiple “Autoantibodies” to Cell Constituents in Systemic Lupus Erythematosus, in Ciba Foundation Symposium - Cellular Aspects of Immunity (eds G. E. W. Wolstenholme and M. O'Connor), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9780470719169.ch20.